Key Highlights
- BIAF shares surged 33.64% pre-market to $13.03, adding to a 47.95% gain in the prior session.
- The company is advancing its CyPath Lung test for surveillance of patients who have completed curative-intent lung cancer treatment.
- More than 680,000 Americans are living with a prior lung cancer diagnosis, representing a large potential surveillance population.
- Published studies show recurrence rates of roughly 20% to 55% for non-small cell lung cancer following treatment.
- Trading Volume reached nearly 45.67 million shares, far above the stock's typical activity.
New Use Case Targets Cancer Survivorship Monitoring
bioAffinity Technologies (NASDAQ:BIAF) shares jumped sharply in pre-market trading after the company announced it is advancing the potential application of its noninvasive lung test for surveillance of lung cancer patients following curative-intent treatment. The expanded use case targets a large and growing population of survivors who face ongoing risk of recurrence or new primary cancers.
bioAffinity Technologies is a San Antonio-based biotechnology company focused on noninvasive detection and monitoring of lung disease. Its flagship test uses flow cytometry and artificial intelligence to analyze patient sputum samples for signs of malignancy, and has previously demonstrated high sensitivity and specificity in detecting early-stage lung cancer.
Test Aims to Complement Imaging in Ambiguous Cases
Physicians quoted in the announcement noted that imaging alone often cannot distinguish between recurrent cancer, a new cancer, and benign post-treatment changes such as scarring or inflammation. The company's binary test result, indicating likely or unlikely malignancy, is positioned to help guide which patients need further invasive investigation versus continued monitoring.
bioAffinity carries a market Capitalization of roughly $4.08 million following the pre-market move, reflecting its small-cap, pre-scale commercial stage. The company has reported losses to date consistent with its early commercialization phase, with the new surveillance application representing a potential expansion of its addressable market rather than an immediate Revenue event.
Clinical Performance Data Still Tied to Original Detection Setting
The company noted that its previously published clinical performance figures, including sensitivity, specificity, and accuracy rates, relate to the test's original use in detecting early-stage lung cancer and have not been separately validated for the new post-treatment surveillance setting. Any expansion into surveillance would likely require additional clinical evidence to support broader adoption.
Large Survivor Population Represents Long-Term Opportunity
With hundreds of thousands of lung cancer survivors requiring ongoing monitoring under existing clinical guidelines, the surveillance application represents a potentially significant long-term market opportunity if supported by further clinical data. Investors will watch for additional validation studies and physician adoption trends as the company builds out this expanded use case alongside its existing detection business.






Please wait processing your request...